NCI Cooperative Group Bank

NCI Cooperative Group Bank
Name	NCI Cooperative Group Bank
Type	Biorepository
Location	Frederick, Maryland
Established	1955

NCI Cooperative Group Bank is a centralized biorepository that supports National Cancer Institute-sponsored clinical trials by storing and distributing human biological specimens for oncology research. The Bank links clinical trial networks such as Children's Oncology Group, ALLIANCE for Clinical Trials in Oncology, SWOG Cancer Research Network, NRG Oncology, and Gynecologic Oncology Group with translational researchers, cooperative groups, and pharmaceutical partners. It operates within infrastructures that include National Institutes of Health, Frederick National Laboratory for Cancer Research, and clinical networks like Eastern Cooperative Oncology Group while interfacing with regulatory entities such as the Food and Drug Administration and the Office for Human Research Protections.

Overview

The Bank functions as a centralized repository integrating specimen accessioning, cryopreservation, inventory management, and distribution for multicenter trials coordinated by entities like National Cancer Institute, Alliance for Clinical Trials in Oncology, SWOG, Children's Oncology Group, and NRG Oncology. Its activities interconnect with translational programs at institutions such as Dana-Farber Cancer Institute, MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, Johns Hopkins Hospital, and Mayo Clinic to support biomarker studies, genomics projects, and correlative science alongside partners including Amgen, Pfizer, Genentech, Novartis, and Roche. The Bank employs laboratory information management systems similar to those used by Clinical Laboratory Improvement Amendments-certified facilities, collaborating with biostatistics cores at Fred Hutchinson Cancer Research Center and data coordinating centers like ICCOG-affiliated groups.

History and Development

Established in the mid-20th century amid expansions of cooperative trial networks such as Eastern Cooperative Oncology Group and Southwest Oncology Group, the Bank evolved in response to initiatives by the National Cancer Institute and policy directives from agencies including National Institutes of Health and oversight from Office for Human Research Protections. Its archival collections expanded with contributions from multicenter protocols like those run by Children's Oncology Group and CALGB before the consolidation of cooperative groups into consortia like ALLIANCE for Clinical Trials in Oncology. Technological advancements paralleled developments at repositories such as Biomax Informatics and genomic platforms pioneered at Broad Institute and Cold Spring Harbor Laboratory, facilitating shifts from formalin-fixed paraffin-embedded archives to fresh-frozen and nucleic-acid-preserved biospecimens used in large-scale efforts like the Cancer Genome Atlas.

Structure and Governance

Governance of the Bank features oversight committees with representatives from cooperative groups including SWOG, Alliance, NRG Oncology, and Children's Oncology Group, alongside policy input from National Cancer Institute program officers and ethics boards patterned after institutional review boards such as those at Georgetown University and Harvard Medical School. Scientific access committees review proposals from investigators at institutions like Yale School of Medicine, University of California, San Francisco, Stanford University, and University of Pennsylvania while legal agreements mirror templates used by Material Transfer Agreement processes and intellectual property frameworks comparable to those at Columbia University. Operational leadership often coordinates with facilities at Frederick National Laboratory for Cancer Research and partners in biobanking consortia like ISBER.

Operations and Services

Core services include specimen accessioning, cryogenic storage, DNA/RNA extraction coordination, histology sectioning, and distribution under controlled conditions to laboratories at Memorial Sloan Kettering Cancer Center, MD Anderson Cancer Center, Dana-Farber Cancer Institute, and commercial partners such as Thermo Fisher Scientific. The Bank integrates laboratory information management systems and inventory platforms used by Clinical and Translational Science Awards hubs and leverages cold chain logistics providers akin to those used by UPS Healthcare and FedEx Clinical Trial Services. It supports assay collaborations with centers like Broad Institute, Salk Institute, and Vanderbilt-Ingram Cancer Center for next-generation sequencing, proteomics, and biomarker validation projects associated with cooperative group protocols.

Contributions to Clinical Research

The Bank has enabled translational research in hematology and oncology areas exemplified by trials from Children's Oncology Group, SWOG, NRG Oncology, and ALLIANCE for Clinical Trials in Oncology, facilitating biomarker discovery, companion diagnostic development, and correlative science that informed approvals by the Food and Drug Administration and guidelines from organizations such as American Society of Clinical Oncology and National Comprehensive Cancer Network. Specimens distributed through the Bank supported genomic analyses in initiatives like the Cancer Genome Atlas and contributed to publications from institutions including Dana-Farber, Memorial Sloan Kettering, and Johns Hopkins, influencing therapeutic development at companies like Roche, Pfizer, and Novartis.

Quality Assurance and Regulatory Compliance

Quality systems at the Bank align with standards from Clinical Laboratory Improvement Amendments, Good Clinical Laboratory Practice guidance, and accreditation bodies allied with College of American Pathologists. Compliance oversight incorporates human-subject protections modeled after Office for Human Research Protections guidance and consent frameworks compatible with regulations under Common Rule and data-sharing policies influenced by National Institutes of Health repositories. Audit trails, chain-of-custody procedures, and proficiency testing are conducted in coordination with external quality programs similar to those from CAP and routine inspections by oversight entities connected to National Cancer Institute contracts.

Criticism and Controversies

The Bank has faced debates over specimen access prioritization, intellectual property claims, and consent scope similar to controversies at other repositories such as disputes seen in repositories linked to Broad Institute and biobank governance discussions at UK Biobank and All of Us Research Program. Critics from academic centers including Harvard Medical School, patient advocacy groups like American Cancer Society, and legal scholars have questioned transparency in Material Transfer Agreement terms, benefit-sharing frameworks, and governance practices, prompting policy reviews influenced by initiatives at NIH and ethics recommendations from panels convened by National Academies of Sciences, Engineering, and Medicine.

Category:Biobanks Category:Cancer research